Latest irritable bowel syndrome Stories
-- GI Clinician and Scientist Most Recently Served in Leadership Positions at Quintiles and the U.S.
-- Leading Clinicians to Discuss Novel Approaches to Treating IBS-C and Preventing C.
Xifaxan® 550 mg is the first-and-only nonsystemic antibiotic approved for the treatment of IBS-D in adults LAVAL, Quebec, May 27, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International,
-First in class treatment for IBS-D treats hallmark symptoms of IBS-D; abdominal pain and diarrhea DUBLIN, May 27, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) announced today that
FREMONT, Calif., May 19, 2015 /PRNewswire/ -- Ardelyx, Inc.
-- Company's Irritable Bowel Syndrome with Constipation (IBS-C) Program to Reduce the Impact of Methane Gas in the Gut on Target to Initiate Phase 2 Clinical Trial in 2Q 2015 -- ROCKVILLE,
Company will focus on probiotics and management of gastroenterological conditions GAITHERSBURG, Md., May 18, 2015 /PRNewswire-USNewswire/ -- ExeGi Pharma, a company focused on developing
- In a group of IBS-M and IBS-D patients, IBgard® reduced eight hallmark symptoms of IBS in as early as 24 hours and further reduced these symptoms at 4 weeks WASHINGTON, May 18, 2015 /PRNewswire/
Survey aims to shed light on irritable bowel syndrome and drive better communication between doctors and their patients BETHESDA, Md., May 8, 2015 /PRNewswire/ -- Today, the American
-- Conference Call and Webcast Today at 5:00 p.m. ET -- FREMONT, Calif., May 5, 2015 /PRNewswire/ -- Ardelyx, Inc.
- The parings of haberdine; also, any kind of fragments.